Fig 1: Analysis of lipid levels in GBA knockout cells. (A and B) Sphingomyelin, ceramide, glucosylceramide, glucosylsphingosine, sphingosine, and sphingosine-1-phosphate were analyzed by mass spectrometry in all knockout cells and compared to their WT counterparts. Mass spectrometry peaks were compared to internal standards, and all data are represented as picomoles of lipid/milligram of protein (mean values shown; n = 6). The data for GlcCer are the same as those displayed graphically in Fig. 2C and D. (C) Mass spectrometry data indicate that GBA may utilize glucosylsphingosine as a secondary substrate (indicated by dashed arrow). De novo synthesis of ceramide is indicated by purple shading.
Fig 2: EGFR degradation is impaired in GBA KO Cells. EGF (50 ng/ml) was added to cells, and the cells were incubated at 37°C. At the indicated times, cell lysates were prepared and subjected to SDS-PAGE and Western blotting for EGFR. (A) Representative Western blots. (B) Quantitation of Western blots indicated significant differences in the levels of EGFR remaining at 2 h postaddition of EGF in GBA KO cells compared to WT cells. Values are normalized to the intensity of GAPDH and are presented as percentages of EGFR remaining compared to cells without EGF stimulation. Data represent means ± SE; n = 6 experiments. *, P < 0.05 (using a Mann-Whitney nonparametric test).
Fig 3: Kinetics of α-syn aggregation in the presence of fibroblast lipid extracts. (A) Lipid extracts from control (n = 4; black) and PD-GBA (n = 4; blue–grey) fibroblast preparations were added to solutions of α-syn and ThT. ThT fluorescence was measured as an indicator of amyloid fibril formation. Kinetics curves are shown from two separate incubations of each subject/patient extract. (Β) Half-times of the reaction of α-syn fibril formation after addition of lipid extracts from control subjects (n = 4) and PD-GBA patients (n = 4). Each circle represents the average of duplicate measurements. Data are shown as individual values and mean ± SEM. Unpaired t-test was performed to compare data. P = 0.0248; F(3,3) = 8.102. *P < 0.05.
Fig 4: Novel protein coding transcripts of GBA1 and GBAP1 show cell type–selective usage.(A) Uniform manifold approximation and projection labeled by characterized cell types in human DLPFC. (B) GBA1 expression from 5′ snRNA-seq of human DLPFC. (C) GBAP1 expression from 5′ snRNA-seq of human DLPFC. (D) Expression of GBA1 ORFs from PacBio Iso-Seq data generated from human iPSC-derived cortical neuron (n = 6), astrocyte (n = 3), and microglia (n = 3) cultures. (E) Expression of GBAP1 ORFs from PacBio Iso-Seq data generated from human iPSC-derived cortical neuron (n = 6), astrocyte (n = 3), and microglia (n = 3) cultures.
Fig 5: Novel GBA1 and GBAP1 transcripts are translated with no GCase activity and impaired lysosomal colocalization with implications for variant interpretation.(A) Immunoblot of H4 GBA1(−/−/−) knockout cells transiently transfected with GBA1 and GBAP1 constructs containing a C-terminal FLAG-tag. GBA1 and GBAP1 expression was detected using FLAG-tag antibody. GAPDH was used as a loading control. The predicted protein sizes are as follows: PB.845.525 (GBAP1; 321 amino acids; 35 kDa), PB.845.2627 (GBA1 affecting GH30 and SP; 219 amino acids; 24 kDa), PB.845.2629 (GBA1 affecting GH30 and SP; 164 amino acids; 18 kDa), PB.845.1693 (GBAP1; 399 amino acids; 44 kDa), ENST00000368373 (GBA1 MANE select; 537 amino acids; 62 kDa), and PB.845.2954 (GBA1 affecting GH30 and SP; 414 amino acids; 46 kDa). (B) Lysosomal enzyme assay of H4 GBA(−/−/−) knockout cells transiently transfected with GBA1 and GBAP1 constructs (C) and in H4 parental. GCase enzyme activity was significantly increased only in H4 parental and GBA(−/−/−) knockout cells transiently transfected with the GBA1 full-length construct (ENST00000368373), compared to the empty vector control (n = 3). (D) Lysosomal colocalization is impaired in novel GBA1 and GBAP1 transcripts. Immunohistochemistry of H4 parental and GBA1(−/−/−) knockout (KO) cells transiently transfected with GBA1 and GBAP1 constructs containing a C-terminal FLAG-tag. Colocalization of GBA1-FLAG and GBAP1-FLAG (green) with CathepsinD (red) was detected using FLAG-tag antibody. (E) Pathogenic GBA1 variants from ClinVar and risk variants from the GBA1-PD browser, which include variants described in PD, annotated onto novel coding GBA1 transcripts plotted using ggtranscript with differences as compared to MANE select (ENST00000368373) highlighted in blue and red.
Supplier Page from Abcam for Anti-GBA antibody [2E2]